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Abstract 
Background: It is often difficult to differentiate between the depressive states seen in late-life depression and late-
onset Alzheimer’ disease (AD) in the clinical setting.
Methods: Thirty-four outpatients were recruited, all fulfilling the criteria of aged 65 years or above, scores of 14 
or more on the Hamilton depression rating scale (HAM-D), and 26 or less on the Mini-Mental State Examination 
(MMSE). At the initial visit, they were administered the Neurobehavioral Cognitive Status Examination (COGNISTAT). At 
1 month, a diagnosis of either senile depression (n = 24) or Alzheimer’ disease (n = 10) was made.
Results: The COGNISTAT revealed that the late-life depression group showed significantly higher scores in orientation 
and comprehension subtests compared with the AD group. At the study endpoint (6 months after treatment), MMSE 
detected significant improvements in the late-life depression group (n = 15), but no changes in the late-onset AD 
group (n = 7). Scores for memory, similarities, and judgment on the second COGNISTAT were significantly improved in 
the depressed group, whereas calculation scores deteriorated significantly in the AD group.
Conclusion: The COGNISTAT could prove useful in differentiating late-life depression from late-onset AD, despite 
similar scores on MMSE.
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Background
It is important to make a clinical distinction between 
late-life depression and Alzheimer’s disease (AD) in geri-
atric patients, because although both diseases exhibit 
dementia or cognitive dysfunction completed suicides 
show close association with major depressive illness, 
especially in the elderly [1]. Previous reviews have docu-
mented the typical clinical and cognitive presentation of 
late-life depression and AD [2, 3]. In primary care, the 
Mini-Mental State Examination (MMSE) is a frequently 
used and convenient assessment tool for global cogni-
tive function [4]. The clock drawing test is also well used 
for assessing visuospatial disabilities in AD. For a more 
accurate assessment of dementia, it is necessary to uti-
lize complex assessment tools, including Wechsler Adult 
Intelligence Scale (WAIS), Wechsler Memory Scale 
(WMS), and the Alzheimer’s Disease Assessment Scale 
(ADAS) [5].
The Neurobehavioral Cognitive Status Examination, 
COGNISTAT, is a short cognitive test for evaluating 
cognitive impairment in AD. Patients with AD showed 
significantly lower scores on many subtests of the COG-
NISTAT compared with healthy, elderly individuals [6, 
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7]. Furthermore, the total number of impaired scores on 
the COGNISTAT was useful for discriminating AD from 
non-AD dementia [8].
Depression in late-life is one of the most common 
mental disorders in old age. The prevalence rate of senile 
depression is almost similar to that of AD in elderly peo-
ple in their seventh decade. Depressive symptoms were 
found in 27 % of patients with AD [9]. It has been shown 
that depressive symptoms are associated with cognitive 
impairment including information processing speed, 
executive function, episodic memory, visuospatial func-
tion, and language processing in elderly patients [2, 10–
12]. Late-life onset depression is associated with a variety 
of cognitive impairments [2]. Late-life depression with 
cognitive impairment and the frequency and severity of 
depressive episodes increase the risk of dementia [13, 
14]. Cognitive impairment in elderly depressive patients 
improves significantly after treatment with antidepres-
sant drugs [15–17]. On the other hand, antidepressant 
therapy in AD patients showed no significant cogni-
tive changes compared to placebo [18], but significantly 
improved depressive symptoms [19]. From a clinical 
point of view, it is likely that accurate discrimination 
between depression and AD could result in more appro-
priate and therefore more beneficial therapies for elderly 
patients [20–22].
Many studies have struggled to develop criteria for 
differentiating between dementia and depression, using 
various cognitive and neuropsychological tests [23–26]. 
However, few analyses have addressed the distinction 
between late-life depression and dementia in elderly 
depressed patients with cognitive dysfunction [23, 24]. 
Furthermore, in these studies, the two cohorts did not 
display similar clinical severity using MMSE. In this 
study, we investigated the utility of COGNISTAT for dis-
criminating between late-life depression and late-onset 
AD using patients with similar scores on MMSE.
Methods
Subjects
All patients were recruited from the outpatient clinics of 
Teikyo University Chiba Medical Center (Ichihara, Chiba, 
Japan), and met the DSM-IV criteria (American Psychi-
atric Association) for a major depressive episode or AD. 
Inclusion criteria for this study were (1) a 26 and below 
score on the MMSE, (2) a 14 and above score on the 
17-item Hamilton Rating Scale for Depression (HAM-D), 
and (3) aged above 65 years. In order to accurately deter-
mine the diagnosis, imaging data from CT, MRI, MRA, 
and/or SPECT were obtained in some cases. Patients 
with cerebral vascular disease were excluded from the 
study. We also tried to exclude patients with mild cogni-
tive impairment [27]. This study was approved by ethics 
committee of Teikyo University Chiba Medical Center 
(study number 13–226), and performed in accordance 
with the declaration of Helsinki. All patients and their 
caregivers provided written informed consent.
Study design
At the initial visit, 34 subjects were administered the 
COGNISTAT. Then, all subjects were diagnosed and 
divided into a late-life depression group (n = 24) or late-
onset AD group (n = 10) during the first month of study. 
Diagnoses were not changed during this period. Next, 
patients were prescribed either antidepressant drugs or 
cholinesterase inhibitors.
After remission or 6  months of treatment (the study 
endpoint), a second COGNISTAT was administered to 
the late-life depression group (n  =  15) and late-onset 
AD group (n  =  7) to determine any changes in cogni-
tive function. The late-life depression group comprised 
patients who received mirtazapine (n = 10), escitalopram 
(n = 3), and paroxetine (n = 2). The late-onset AD group 
received donepezil (n = 4), galantamine (n = 2), and par-
oxetine (n = 1).
For further analysis, we divided patients with late-life 
depression into remission group (n = 10) and non-remis-
sion group (n = 5), depending on whether they achieved 
remission during the study. We defined remission as a 
score of 7 or less on the HAM-D.
Measurement of cognitive function
COGNISTAT is typically utilized for assessing multiple 
cognitive functions, using a screen-metric method [28]. 
Generally, it takes 15–20  min to administer. The COG-
NISTAT consists of 10 subsets, including orientation, 
attention, comprehension, repetition, naming, construc-
tion, memory, calculation, similarities, and judgment. 
The three components, namely comprehension, rep-
etition, and naming, determine the language ability. The 
two components of similarities and judgment determine 
the ability to reason. However, these subtests lack the 
strength of detection compared with other neurocogni-
tive tests, such as WMS and WAIS. The normative data 
of elderly people were developed to aid diagnosis of cog-
nitive impairment, since aging influences some compo-
nents of construction, memory, and similarities on the 
COGNISTAT [29–31].
Statistical analysis
Multiple analysis of variance (MANOVA) was used to 
determine the simultaneous existence of significant dif-
ferences. Statistical analysis was performed using Stu-
dent’s t-test or paired t-test for parametric data, or the 
Chi square test for non-parametric data. Correlations 
among scores from COGNISTAT were examined using 
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the Pearson correlation coefficient. Differences were con-
sidered significant when p values were less than 0.05 for 
ANOVA, t-test, and Chi square test, and 0.01 for correla-
tion coefficient.
We calculated the sensitivity and specificity of COG-
NISTAT for late-life depression, using COGNISTAT 
subtests with a significant difference between late-life 
depression and AD in a cross-sectional design. The sen-
sitivity and specificity were defined as stated previously 
[32]. The criteria of normal or impaired states on the 
COGNISTAT were defined using healthy elderly individ-
uals as standards [33].
Sensitivity to late-life depression was defined as the 
following: the results of COGNISTAT suggest late-life 
depression when the patient was diagnosed as hav-
ing depression. Sensitivity was calculated by the ratio of 
patients with late-life depression with scores above the 
set criteria to the total number of patients with late-life 
depression.
Specificity to late-life depression was defined as the fol-
lowing: the results of COGNISTAT did not suggest late-
life depression, when the patient was diagnosed as having 
AD. Specificity to late-life depression was calculated by 
the ratio of AD patients with scores below the set criteria 
to the total number of AD patients.
Criteria for calculating sensitivity and specificity are an 
orientation score of 10 and/or a comprehension score of 
5, because of the significant differences on both of scores 
between late-life patients and late-onset AD patients.
Results
Neuropsychological test results at baseline
Of the 34 patients, 24 were diagnosed as suffering major 
depressive disorder, and 10 were diagnosed as having AD, 
1 month after their first study. The baseline demographic 
characteristics are presented in Table 1. The patients with 
late-life depression and late-onset AD did not differ in 
age, sex, or MMSE scores. However, late-life depression 
patients showed significantly higher HAM-D scores com-
pared with late-onset AD patients. On the COGNISTAT 
components, MANOVA indicated a significant group 
effect (F = 3.532, p = 0.006). Subsequent Student’s t-test 
demonstrated that the late-life depression group had 
significantly higher scores for orientation (t  =  3.141, 
p = 0.010) and comprehension (t = 2.262, p = 0.045) on 
the COGNISTAT (Fig. 1).
For all participants, MMSE scores displayed significant 
correlation with orientation and calculation scores on 
the COGNISTAT (Table 2), whereas HAM-D showed no 
significant correlation with MMSE or COGNISTAT sub-
components (data not shown).
Furthermore, we calculated sensitivity and specific-
ity to assess the utility of this method for differentiating 
between late-life depression and late-onset AD, using 
scores from orientation and/or comprehension subtests. 
When the standard for late-life depression was defined as 
a score of 10 or more for orientation, sensitivity was 96 % 
and specificity was 50 %. When the standard criterion of 
late-life depression was defined as 5 or more for scores 
on the comprehension, sensitivity was 96 % and specific-
ity was 40  %. Moreover, when the standard for late-life 
depression was set at scores of 10 or more on orientation, 
and 5 or more on comprehension, sensitivity was 92  % 
and specificity was 60 %.
In the MMSE, when a cut-off point sets the standard 
criterion for late-life depression at a score of 24 or more, 
sensitivity and specificity of MMSE to late-life depression 
were 58  % and 60  %, respectively. When a cut-off point 
sets the standard criterion at a score of 22 or more, sen-
sitivity and specificity of MMSE to late-life depression 
were 79 % and 50 %, respectively.
Comparison of cognitive function between baseline 
and endpoint in each group
Fifteen of 24 patients (62.5  %) with late-life depres-
sion and seven of 10 patients (70.0  %) with late-onset 
AD completed this longitudinal research. At the study 
endpoint, defined as 6  months after treatment, MMSE 
detected significant improvements in the senile depres-
sion group (from 22.7 to 24.9, t  =  2.402, p  =  0.031), 
Table 1 Comparison of characteristics between the late-life depression group and Alzheimer’s disease group
Data are shown as mean ± SD
HAM-D the 17-item Hamilton Rating Scale for Depression, MMSE Mini-Mental State Examination, AD Alzheimer’s disease
* p <0.05 by Student’s t-test
Late-life depression  
group (n = 24)
Late-onset AD  
group (n = 10)
P
Sex (M/F) 6/18 5/5 0.156
Age (years) 72.4 ± 7.1 76.0 ± 5.9 0.171
HAM-D 21.3 ± 7.1 16.1 ± 4.7* 0.043
MMSE 23.4 ± 2.8 21.9 ± 2.8 0.163
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Fig. 1 The COGNISTAT scores at baseline. Student’s t-test showed significant differences between the late-life depression group and late-onset 
Alzheimer’s disease group for orientation and comprehension subtests. * p < 0.05
Table 2 Correlation between MMSE and COGNISTAT subtests in all patients (n = 34)
Data are shown as mean ± SD
* p <0.01
Ori orientation subtest, Atten attention subtest, Comp comprehension subtest, Rep repetition subtest, Nam naming subtest, Const construction subtest, Mem memory 
subtest, Cal calculation subtest, Sim similarities subtest, Judg judgment subtest
1 2 3 4 5 6 7 8 9 10 11
MMSE Ori Atten Comp Rep Nam Const Mem Cal Sim Judg
Language Reasoning
1. MMSE 0.542* 0.247 0.337 0.338 0.275 0.166 0.409 0.590* 0.283 0.227
2. Orientation 0.253 0.341 0.303 0.419 0.003 0.191 0.395 0.187 0.309
3. Attention 0.194 0.460* 0.416 0.442* 0.099 0.255 0.359 0.529*
4. Comprehension 0.363 0.099 0.075 0.164 0.502* 0.546* 0.497*
5. Repetition 0.374 0.326 0.008 0.369 0.318 0.32
6. Naming 0.393 0.082 0.275 0.437* 0.368
7. Construction 0.09 0.316 0.29 0.514*
8. Memory 0.037 0.172 0.077
9. Calculation 0.603* 0.614*
10. Similarities 0.599*
11. Judgment
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whereas no changes were observed in the late-onset AD 
group (from 22.1 to 21.3, t = 0.446, p = 0.671). HAM-D 
demonstrated significant improvement in the late-life 
depression group (from 21.6 to 9.3, t = 10.931, p <0.001), 
and a non-significant trend for improvement in the AD 
group (from 16.6 to 10.9, t = 1.498, p = 0.185).
As shown in Fig. 2, between baseline and endpoint, the 
late-life depression group showed significant improve-
ment of some cognitive functions, such as memory 
(t = 2.385, p = 0.032), similarities (t = 2.739, p = 0.016), 
and judgment (t  =  2.739, p  =  0.016). The late-onset 
AD group showed a significant reduction in calculation 
scores (t =  2.500, p =  0.047) at endpoint, compared to 
baseline.
Effects of cognitive performance at baseline on the 
treatment outcome in late-life depression
Of the 15 patients with late-life depression who com-
pleted the 6-month study period, 10 were classified into 
a remitted group and 5 into a non-remitted group. The 
remitted group, who scored 7 and below on the HAM-D, 
showed recovery on the MMSE (t = 2.493, p = 0.034) and 
judgment (t = 3.284, p = 0.009), while the non-remitted 
group, who scored 10 and above on the HAM-D, showed 
a similar trend without statistical significance in these 
two categories.
Discussion
The first finding of this study was that late-onset AD 
patients suffered worse impairment of orientation and 
comprehension as measured on the COGNISTAT, rela-
tive to patients with late-life depression, despite no sig-
nificant difference in MMSE scores at baseline between 
two groups. The MMSE score showed significant cor-
relation with orientation and calculation scores, but not 
the comprehension score, indicating that orientation and 
calculation subtests share stronger relationships with 
dementia symptoms in this test. Interestingly, the cal-
culation subtest showed a strong relationship with sub-
tests for comprehension, similarities, and judgment on 
the COGNISTAT. However, HAM-D scores showed no 
significant relationship with any scores on the COGNI-
STAT in either patient group (data not shown). It appears 
therefore that subtests for orientation and comprehen-
sion on the COGNISTAT are capable of discriminating 
late-life depression from late-onset AD, independent of 
depressive symptoms, in patients suffering both a depres-
sive state and cognitive impairment. A previous study 
reported that subtests for comprehension, construc-
tion, and memory on the COGNISTAT were useful for 
differentiating depression from dementia [23], a finding 
which is in partial agreement with this study. It should 
be noted that this study recruited patients in early onset 
of depression and cognitive dysfunction. Thus, the dis-
ease severity of the study subjects was light to moder-
ate, potentially increasing the difficulty of discriminating 
between the two types of disease. Further studies will be 
needed to clarify this issue.
The sensitivity and specificity of COGNISTAT to late-
life depression were 92  % and 60  %, respectively, when 
the standard scores for late-life depression were set at 10 
or more on orientation, and 5 or more on comprehen-
sion. These findings indicate that COGNISTAT is able 
to discriminate late-life depression from late-onset AD 
in elderly patients. Sensitivity and specificity of MMSE 
to late-life depression were 79 % and 50 %, respectively, 
when the standard scores for late-life depression were 
set at a score of 22 or more. Previous studies showed that 
COGNISTAT was superior to MMSE in determining 
sensitivity to cognitive impairment [34, 35], but inferior 
to MMSE in specificity [35], which is partially in agree-
ment with the present study.
The second finding was that the late-life depression 
group exhibited significant improvement in memory, 
similarities, and judgment scores on the COGNISTAT, 
whereas the late-onset AD group exhibited significant 
worsening in the calculation subtest at the endpoint. It 
is plausible that the reduction in subtests for memory, 
similarities, and judgment, was due to cognitive dysfunc-
tion in the depressive state. As shown in Table  2, simi-
larities and judgment scores were strongly related to the 
comprehension subtest, which is one of two important 
factors for discriminating late-life depression from late-
onset AD at baseline. This is supported by previous stud-
ies which found that antidepressant treatment improved 
global cognitive function in elderly depressed patients 
[16, 17, 33].
The late-life depression group showed significant recov-
ery in HAM-D and to a lesser extent in MMSE scores. 
This is in good agreement with previous studies showing 
that cognitive dysfunction persists to some extent, even 
though depressive symptoms show sufficient improve-
ment in geriatric depression [15, 36]. However, the late-
onset AD group showed non-significant improvement 
of depressive symptoms without any changes in MMSE 
scores. In a clinical context, the pattern of changes is 
very similar between the two groups. Therefore, nei-
ther HAM-D nor MMSE is sufficient for discrimina-
tion between late-life depression and late-onset AD. In a 
previous study, the memory scale and at least one other 
scale on the COGNISTAT were useful for identifying 
dementia, including AD [8]. However, prior to treatment, 
depressed patients also showed reduced memory per-
formance [17]. Cued recall was useful in differentiating 
early AD and cognitive dysfunction from depression in 
elderly individuals [37]. A decline in performance on the 
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Fig. 2 The COGNISTAT scores at baseline and endpoint. a Comparison of COGNISTAT scores at baseline and endpoint in the late-life depression 
group. Scores for memory, similarities, and judgment were significantly higher at endpoint compared with baseline. b Comparison of COGNISTAT 
scores at baseline and endpoint in the late-onset Alzheimer’s disease group. Score for calculations was significantly lower at endpoint than at 
baseline. * p < 0.05
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test of episodic memory and subsequent declines in tests 
for executive function were observed before diagnosis in 
preclinical AD [38]. In this study, baseline memory scores 
on the COGNISTAT were not impaired in late-onset AD 
patients with reference to the criteria for elderly indi-
viduals. This might well be due to cognitive dysfunction 
within the present cohort.
Both similarities and judgment subtests on COGNI-
STAT are characterized by reasoning. Previous studies 
have shown that these subtests reflect executive function, 
working memory, planning, inhibition, and concept gen-
eration [39–41]. Although acetylcholinesterase inhibi-
tor therapy failed to improve executive function in AD 
patients [42], antidepressant therapy improved cognitive 
impairment in elderly patients with major depression 
[43]. Therefore, it is likely that in the late-life depression 
group, impairment of similarities and judgment on the 
COGNISTAT could be due to a diminished reasoning.
Neuropsychological dysfunction of late-life depres-
sion is typified by slowed information processing, which 
influences all domains of cognition, including memory 
and executive function [10]. Furthermore, slow cognitive 
processing speed is the core cognitive deficit in late-life 
depression and is closely followed by executive function 
[11]. Therefore, improvement of memory, similarities, 
and judgment scores from late-life depressed patients in 
this study may be the result of improved information pro-
cessing speed, mediated by antidepressant therapy. Fur-
ther studies will be needed to examine the relationship 
between cognitive function on the COGNISTAT and 
information processing speed, as it was not addressed in 
this study.
This study has several limitations. First, the sam-
ple size is relatively small. Second, there was a signifi-
cant difference on the HAM-D score between late-life 
depression and AD groups at baseline. This may reflect 
the fact that AD patients tend to underestimate their 
depressive symptoms [44], and the depressive state in 
AD patients is typically less severe and becomes less 
pronounced as the dementia symptoms progress [3]. 
Finally, patients in the AD group do not suffer mild 
cognitive impairment by clinical diagnosis, whereas the 
depression group may contain patients with mild cogni-
tive impairment, since it was reported that patients with 
mild cognitive impairment suffer from major depression 
(20 %) [45].
Conclusion
COGNISTAT is capable of differentiating late-life depres-
sion from late-onset AD, based on higher scores in orien-
tation and comprehension subtests, among patients with 
both depressive symptoms and cognitive dysfunction at 
baseline, despite similar scores on MMSE. At endpoint, 
patients with late-life depression showed significant 
improvement in subtests for memory, similarities, and 
judgment, whereas patients with late-onset AD showed 
significant worsening in the calculation subtest compared 
to baseline.
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